JPRN-UMIN000000622已完成未知
Heart Failure management by COmbination of STatin and ARB - HF-COSTAR
Department of Cardiovascular Medicine, Tokyo Medical and Dental University0 个研究点目标入组 40 人开始时间: 2007年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The patient who is improper of this study.
研究者
相似试验
已完成
不适用
Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zincheart failureJPRN-UMIN000020203Tokorozawa Heart Center, Medical Corporation Ouyuukai50
尚未招募
4 期
ovel Interventions in Heart Failure with Preserved Ejection Fraction using TadalafilHeart Failure with Preserved Ejection FractionCardiovascular - Other cardiovascular diseasesACTRN12612000684820South Australian Health and Medical Reseasrch Institute20
尚未招募
4 期
ovel Interventions in Heart Failure with Preserved Ejection Fraction using ivabradineHeart Failure with Preserved Ejection FractionCardiovascular - Other cardiovascular diseasesACTRN12612000710820South Australian Health and Medical Research Institute20
进行中（未招募）
1 期
Can the heart drug enalapril prevent heart damage in patients with newly diagnosed breast cancer and lymphoma receiving chemotherapy?Prevention of cardiotoxicityMedDRA version: 20.0Level: PTClassification code 10048610Term: CardiotoxicitySystem Organ Class: 10007541 - Cardiac disordersEUCTR2017-001094-16-GBSouth Tees NHS Foundation Trust170
已完成
不适用
Improve Management of heart failure with Procalcitonin - Biomarkers in Cardiology 18 (Short title: IMPACT-EU)10019280bacterial infectionheart failureNL-OMON42767Thermo Fisher Scientific BRAHMS GmbH50